文献速递肿瘤 PET/CT

68Ga-PSMA-617 PET/CT:预测前列腺癌患者风险分层与转移风险的有前景新技术

68Ga-PSMA-617 PET/CT: a promising new technique for predicting risk stratification and metastatic risk of prostate cancer patients.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-05-02

本研究回顾性分析50例经穿刺活检新诊断前列腺癌患者的68Ga-PSMA-617 PET/CT及临床资料,其中训练集40例、测试集10例。依据NCCN指南风险分层标准将患者简化为低-中危组与高危组,采用原发灶SUVmax、前列腺内PSMA衍生肿瘤体积(iPSMA-TV)和前列腺内PSMA总病灶(iTL-PSMA)建立单变量逻辑回归模型。结果显示上述半定量参数均可有效预测高危前列腺癌,iPSMA-TV和iTL-PSMA模型可预测转移风险,而SUVmax模型不能预测转移风险。

要点

  • SUVmax、iPSMA-TV和iTL-PSMA模型预测高危前列腺癌的AUC分别为0.843、0.802和0.900。
  • 测试集中iTL-PSMA模型预测高危前列腺癌的敏感度和特异度分别为87.5%和100%。
  • iPSMA-TV和iTL-PSMA模型预测转移风险的AUC分别为0.863和0.848,SUVmax模型不能预测转移风险。

核心结论

  • 68Ga-PSMA-617 PET/CT的半定量分析指标可作为「影像生物标志物」预测前列腺癌的风险分层和转移风险。

研究设计与样本

  • 回顾性分析连续纳入的50例经穿刺活检确诊的新诊断前列腺癌患者,其中训练集40例、测试集10例。
  • 所有患者行68Ga-PSMA-617 PET/CT并获取临床数据,半定量分析获得原发灶SUVmax、iPSMA-TV和iTL-PSMA。
  • 依据NCCN指南前列腺癌风险分层标准,将全部患者简化为低-中危组或高危组。
  • 采用68Ga-PSMA-617 PET/CT半定量参数建立预测高危前列腺癌及其转移风险的单变量逻辑回归模型。

主要发现

  • 训练集中30/40(75%)患者为高危前列腺癌,10/40(25%)为低-中危前列腺癌;测试集中8/10(80%)为高危前列腺癌,2/10(20%)为低-中危前列腺癌。
  • 以SUVmax、iPSMA-TV和iTL-PSMA建立的单变量逻辑回归模型均可有效预测高危前列腺癌,ROC的AUC分别为0.843、0.802和0.900。
  • 基于测试集,各模型预测高危前列腺癌的敏感度和特异度分别为:SUVmax模型87.5%和50%,iPSMA-TV模型62.5%和100%,iTL-PSMA模型87.5%和100%。
  • 基于iPSMA-TV和iTL-PSMA的预测模型可预测前列腺癌转移风险,ROC的AUC分别为0.863和0.848。
  • 基于SUVmax的预测模型不能预测转移风险。

关键数值与推荐

  • 采用NCCN指南前列腺癌风险分层标准,将患者简化为低-中危组或高危组。
  • SUVmax模型预测高危前列腺癌的AUC为0.843,测试集敏感度87.5%、特异度50%。
  • iPSMA-TV模型预测高危前列腺癌的AUC为0.802,测试集敏感度62.5%、特异度100%。
  • iTL-PSMA模型预测高危前列腺癌的AUC为0.900,测试集敏感度87.5%、特异度100%。
  • iPSMA-TV模型预测转移风险的AUC为0.863,iTL-PSMA模型预测转移风险的AUC为0.848。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of this study was to investigate the performance of 68Ga-PSMA-617 PET/CT in predicting risk stratification and metastatic risk of prostate cancer. METHODS: Fifty newly diagnosed patients with prostate cancer as confirmed by needle biopsy were continuously included, 40 in a train set and ten in a test set. 68Ga-PSMA-617 PET/CT and clinical data of all patients were retrospectively analyzed. Semi-quantitative analysis of PET images provided maximum standardized uptake (SUVmax) of primary prostate cancer and volumetric parameters including intraprostatic PSMA-derived tumor volume (iPSMA-TV) and intraprostatic total lesion PSMA (iTL-PSMA). According to prostate cancer risk stratification criteria of the NCCN Guideline, all patients were simplified into a low-intermediate risk group or a high-risk group. The semi-quantitative parameters of 68Ga-PSMA-617 PET/CT were used to establish a univariate logistic regression model for high-risk prostate cancer and its metastatic risk, and to evaluate the diagnostic efficacy of the predictive model. RESULTS: In the train set, 30/40 (75%) patients had high-risk prostate cancer and 10/40 (25%) patients had low-to-moderate-risk prostate cancer; in the test set, 8/10 (80%) patients had high-risk prostate cancer while 2/10 (20%) had low-intermediate risk prostate cancer. The univariate logistic regression model established with SUVmax, iPSMA-TV and iTL-PSMA could all effectively predict high-risk prostate cancer; the AUC of ROC were 0.843, 0.802 and 0.900, respectively. Based on the test set, the sensitivity and specificity of each model were 87.5% and 50% for SUVmax, 62.5% and 100% for iPSMA-TV, and 87.5% and 100% for iTL-PSMA, respectively. The iPSMA-TV and iTL-PSMA-based predictive model could predict the metastatic risk of prostate cancer, the AUC of ROC was 0.863 and 0.848, respectively, but the SUVmax-based prediction model could not predict metastatic risk. CONCLUSIONS: Semi-quantitative analysis indexes of 68Ga-PSMA-617 PET/CT imaging can be used as "imaging biomarkers" to predict risk stratification and metastatic risk of prostate cancer.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Liu C, Liu T, Zhang N, et al. 68Ga-PSMA-617 PET/CT: a promising new technique for predicting risk stratification and metastatic risk of prostate cancer patients. Eur J Nucl Med Mol Imaging. 2018. PMID: 29717333. doi:10.1007/s00259-018-4037-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。